These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29133887)

  • 1. A Complementary Scale of Biased Agonism for Agonists with Differing Maximal Responses.
    Burgueño J; Pujol M; Monroy X; Roche D; Varela MJ; Merlos M; Giraldo J
    Sci Rep; 2017 Nov; 7(1):15389. PubMed ID: 29133887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data.
    Stott LA; Hall DA; Holliday ND
    Biochem Pharmacol; 2016 Feb; 101():1-12. PubMed ID: 26478533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor.
    Thompson GL; Lane JR; Coudrat T; Sexton PM; Christopoulos A; Canals M
    Biochem Pharmacol; 2016 Aug; 113():70-87. PubMed ID: 27286929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling and simulation of biased agonism dynamics at a G protein-coupled receptor.
    Bridge LJ; Mead J; Frattini E; Winfield I; Ladds G
    J Theor Biol; 2018 Apr; 442():44-65. PubMed ID: 29337260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window.
    Gillis A; Sreenivasan V; Christie MJ
    Mol Pharmacol; 2020 Oct; 98(4):410-424. PubMed ID: 32665252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel method for analyzing extremely biased agonism at G protein-coupled receptors.
    Stahl EL; Zhou L; Ehlert FJ; Bohn LM
    Mol Pharmacol; 2015 May; 87(5):866-77. PubMed ID: 25680753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of functional selectivity through G protein-dependent and -independent signaling pathways at the adrenergic α(2C) receptor.
    Kurko D; Kapui Z; Nagy J; Lendvai B; Kolok S
    Brain Res Bull; 2014 Aug; 107():89-101. PubMed ID: 25080296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor.
    Thompson GL; Lane JR; Coudrat T; Sexton PM; Christopoulos A; Canals M
    Mol Pharmacol; 2015 Aug; 88(2):335-46. PubMed ID: 26013541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.
    Shonberg J; Lopez L; Scammells PJ; Christopoulos A; Capuano B; Lane JR
    Med Res Rev; 2014 Nov; 34(6):1286-330. PubMed ID: 24796277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label-free cell phenotypic assessment of the biased agonism and efficacy of agonists at the endogenous muscarinic M3 receptors.
    Deng H; Sun H; Fang Y
    J Pharmacol Toxicol Methods; 2013; 68(3):323-33. PubMed ID: 23933114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists.
    Stahl EL; Bohn LM
    Biochemistry; 2022 Sep; 61(18):1923-1935. PubMed ID: 34468132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biased receptor functionality versus biased agonism in G-protein-coupled receptors.
    Franco R; Aguinaga D; Jiménez J; Lillo J; Martínez-Pinilla E; Navarro G
    Biomol Concepts; 2018 Dec; 9(1):143-154. PubMed ID: 30864350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity.
    Kenakin T
    Br J Pharmacol; 2010 Jul; 160(5):1045-7. PubMed ID: 20590598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into biased agonism at G protein-coupled receptors and their potential for drug design.
    Martí-Solano M; Guixà-González R; Sanz F; Pastor M; Selent J
    Curr Pharm Des; 2013; 19(28):5156-66. PubMed ID: 23621547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple method for quantifying functional selectivity and agonist bias.
    Kenakin T; Watson C; Muniz-Medina V; Christopoulos A; Novick S
    ACS Chem Neurosci; 2012 Mar; 3(3):193-203. PubMed ID: 22860188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A method for the quantification of biased signalling at constitutively active receptors.
    Hall DA; Giraldo J
    Br J Pharmacol; 2018 Jun; 175(11):2046-2062. PubMed ID: 29498414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conceptual and experimental issues in biased agonism.
    Onaran HO; Costa T
    Cell Signal; 2021 Jun; 82():109955. PubMed ID: 33607257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evasive nature of drug efficacy: implications for drug discovery.
    Galandrin S; Oligny-Longpré G; Bouvier M
    Trends Pharmacol Sci; 2007 Aug; 28(8):423-30. PubMed ID: 17659355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.
    Luttrell LM; Maudsley S; Bohn LM
    Mol Pharmacol; 2015 Sep; 88(3):579-88. PubMed ID: 26134495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G Protein-coupled Receptor Biased Agonism.
    Hodavance SY; Gareri C; Torok RD; Rockman HA
    J Cardiovasc Pharmacol; 2016 Mar; 67(3):193-202. PubMed ID: 26751266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.